

## EQUALITY AND DIVERSITY RAPID IMPACT ASSESSMENT REPORT

The master copy of this report is held by the NHS QIS Equality and Diversity Officer

| <b>EQRIA SUMMARY</b>                   |   |  |   |
|--|---|--|---|
| <b>Name of Product</b>                 | Evidence Note: The use of recombinant Factor VIIa (rFVIIa) in people with haemophilia                     |  | <b>This is a:</b><br>Product                    |
| <b>Owning Unit/Directorate:</b>        | HSRA Unit, Guidance and Standards Directorate   |  |   |
| <b>Names / job titles of assessors</b> | Lead: Evidence Notes Coordinator<br>1) Medical Writer<br>2) Statistician<br>3) Interim General Manager    | <b>Date(s) of assessment:</b>                                  | Start: 19 June 2007<br><br>Finish: 19 June 2007 |
| <b>EQIA results</b>                    | Adverse impacts: No<br><br>If adverse, indicate level of significance:                      Low      High | Positive impacts: Yes  |   |
| <b>Recommended Action</b>              | Issue Product: Yes  | Review date of Product: N/A, as Evidence Notes not reviewed.   |   |
|  | Withdraw the Product from use: No   | Revision date of Product: N/A, as Evidence Notes not reviewed. |   |
|  | Undertake a full equality and diversity impact assessment: No   | FIA planned completion date: N/A                               |   |
| <b>Agreed by Head of Unit</b>          | Name: Elaine Harrow   | Date: 19 June 2007   |   |

## EQIA SUMMARY

### Summary of positive impacts and affected groups

Positive impacts relate to people with disabilities. Evidence Note is in contrasting colours and available in large print, or large text on the website (w3c compliant), which are helpful for partially-sighted people. It is available in Braille on request, which is helpful for people who do not have sight. The text is left justified, which is helpful for people with dyslexia. Audiotape and CD formats are available on request, which are helpful to people who do not have sight or cannot read. Using the appropriate terminology for people with the disease.

### Summary of adverse impacts and affected groups

None, since the purpose of the Evidence Note is to answer a request from an individual planner for factual information and not to make any recommendations. The affected groups for the purpose of this Evidence Note are planners who requested this product. The only potential issues were around accessibility which were considered to have a high positive impact.

### Summary of consultation undertaken

There is no consultation required because the purpose of the Evidence Note is to summarise current published evidence without making recommendation.

### Additional information and evidence required

None

### Recommendations

To publish the Evidence Note. If any NHS Boards take the decision to change practice as a result of the evidence summarised within this Evidence Note, they should undertake an EQIA assessment.

### Give reasons to explain why a full EQIA has / has not been recommended

No adverse impacts were identified as explained above.

### Completed by Lead Assessor

Name: Ailsa Brown

Date: 19 June 2007

*If you would like a copy of the impact assessment report or prefer to read the report in an alternative format, please contact the Public Involvement Unit:*

*Phone: 0131 623 4300 / Textphone: 0131 623 4383*